Medpace Holdings, Inc. with ticker code (MEDP) have now 4 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 273 and 265 with the average target price sitting at $269.50. Now with the previous closing price of $272.28 this would imply there is a potential downside of -1.0%. It’s also worth noting that there is a 50 day moving average of $253.67 and the 200 day MA is $225.63. The market cap for the company is 7.93B. The stock price for the company is currently 258.52 USD
The potential market cap would be $7,851,427,191 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 30.34, revenue per share of 57.77 and a 14.47% return on assets.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focuses on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
